As disruption of many of these coactivators impairs the estrogen response, they are attractive drug targets and various inhibitors against some of these factors were reported to exhibit anti-proliferative activity in ER+ breast cancer (100-102) or androgen receptor (AR)+ castrate-resistant prostate cancer (103, 104) preclinical models. Here, ESR1 is linked to prostate carcinoma.